Vimian Group (VIMIAN) investor relations material

Executive summary

• Achieved 17% year-over-year revenue growth to EUR 121.6 million in Q2 2026, with double-digit organic growth across all segments and strong margin expansion, outpacing the global animal health market.

• Adjusted EBITA increased 17% to EUR 29.7 million, with a margin of 24.5%, driven by robust performance in MedTech and other segments.

• Four acquisitions closed year-to-date, strengthening the group’s global position and maintaining an active M&A pipeline.

• Received an MSCI ESG rating upgrade to AAA, ranking among the top 19% of global peers.

• Profit for the period was EUR 8.8 million, with EPS at EUR 0.02.

Financial highlights

• Revenue grew 17% year-over-year to EUR 121.6 million in Q2 2026.

• Organic growth was 12%, with 6% from acquisitions and -1% from currency effects.

• Adjusted EBITA margin at 24.5%; operating profit (EBIT) rose 54% to EUR 22.3 million.

• Net income for the quarter was EUR 8.8 million; cash flow from operating activities at EUR 3.8 million, impacted by tax timing and working capital.

• Net financial items were EUR -8.0 million, impacted by financing expenses, contingent consideration adjustments, and exchange rate effects.

Outlook and guidance

• Focus for the remainder of 2026 is on executing the M&A pipeline, driving organic growth, and building a stronger cross-company culture.

• Expect continued slow single-digit organic growth in U.S. Orthopedics for H2 2026, with ongoing market softness.

• Confident in steady margin improvement in MedTech and Dental segments.

• M&A activity expected to remain high, with both small and large opportunities in the pipeline.

• The company is well-positioned in growing animal health market niches and expects continued above-market organic growth.